These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26799124)

  • 1. The introduction of generic risperidone in Medicare Part D.
    Fung V; Price M; Busch AB; Landrum MB; Fireman B; Nierenberg AA; Newhouse JP; Hsu J
    Am J Manag Care; 2016 Jan; 22(1):41-8. PubMed ID: 26799124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse clinical events among medicare beneficiaries using antipsychotic drugs: linking health insurance benefits and clinical needs.
    Fung V; Price M; Busch AB; Landrum MB; Fireman B; Nierenberg A; Dow WH; Hui R; Frank R; Newhouse JP; Hsu J
    Med Care; 2013 Jul; 51(7):614-21. PubMed ID: 23752219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.
    Treur M; Heeg B; Möller HJ; Schmeding A; van Hout B
    BMC Health Serv Res; 2009 Feb; 9():32. PubMed ID: 19226465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure.
    Baik SH; Rollman BL; Reynolds CF; Lave JR; Smith KJ; Zhang Y
    J Ment Health Policy Econ; 2012 Sep; 15(3):105-18. PubMed ID: 23001279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
    Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
    Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
    Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
    Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
    Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
    JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disenrollment from Medicare HMOs.
    Call KT; Dowd BE; Feldman R; Lurie N; McBean MA; Maciejewski M
    Am J Manag Care; 2001 Jan; 7(1):37-51. PubMed ID: 11209449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry.
    O'Brien EC; McCoy LA; Thomas L; Peterson ED; Wang TY
    Am Heart J; 2015 Jul; 170(1):55-61. PubMed ID: 26093864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes.
    Fung V; Mangione CM; Huang J; Turk N; Quiter ES; Schmittdiel JA; Hsu J
    Health Serv Res; 2010 Apr; 45(2):355-75. PubMed ID: 20050931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.
    Lessing C; Ashton T; Davis P
    Adm Policy Ment Health; 2015 Nov; 42(6):695-703. PubMed ID: 25331449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of Medicare plan choices: are beneficiaries more influenced by premiums or benefits?
    Jacobs PD; Buntin MB
    Am J Manag Care; 2015 Jul; 21(7):498-504. PubMed ID: 26247740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
    Godman B; Petzold M; Bennett K; Bennie M; Bucsics A; Finlayson AE; Martin A; Persson M; Piessnegger J; Raschi E; Simoens S; Zara C; Barbui C
    BMC Med; 2014 Jun; 12():98. PubMed ID: 24927744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic atypical antipsychotic drugs in Belgium: their influence and implications.
    Godman B; De Bruyn K; Miranda J; Raschi E; Bennie M; Barbui C; Simoens S
    J Comp Eff Res; 2013 Nov; 2(6):551-61. PubMed ID: 24236794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
    Mishuk AU; Fasina I; Qian J
    Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries.
    Sacks NC; Burgess JF; Cabral HJ; Pizer SD; McDonnell ME
    J Gen Intern Med; 2013 Jul; 28(7):876-85. PubMed ID: 23404199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder.
    Smith KJ; Baik SH; Reynolds CF; Rollman BL; Zhang Y
    Am J Manag Care; 2013 Feb; 19(2):e55-63. PubMed ID: 23448115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.